| Recruiting | A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated O NCT06927375 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 4 |
| Recruiting | Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy NCT06590220 | Shanghai Changzheng Hospital | — |
| Recruiting | Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial) NCT06392906 | Janjira Petsuksiri | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease NCT06226545 | Lassen Therapeutics Inc. | Phase 2 |
| Not Yet Recruiting | A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy NCT03098225 | University of Pisa | Phase 4 |
| Completed | A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy NCT06269393 | Peking University People's Hospital | Phase 3 |
| Recruiting | Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TE NCT06112340 | Sling Therapeutics, Inc. | Phase 2 / Phase 3 |
| Withdrawn | Efficacy and Safety of Tocilizumab for TAO NCT06087731 | Sun Yat-sen University | Phase 2 |
| Recruiting | Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease NCT04936854 | Haukeland University Hospital | Phase 2 |
| Recruiting | Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated Ophthalmopathy NCT07124572 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Active Not Recruiting | A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) NCT05276063 | Sling Therapeutics, Inc. | Phase 2 / Phase 3 |
| Recruiting | Multi-model Image of Doxycycline in TAO NCT05112211 | Sun Yat-sen University | N/A |
| Unknown | Multi-model Image of Immunosuppressive Agents in TAO NCT05110040 | Sun Yat-sen University | N/A |
| Recruiting | Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery. NCT04662190 | Althaia Xarxa Assistencial Universitària de Manresa | N/A |
| Unknown | Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy NCT04919694 | Sun Yat-sen University | N/A |
| Unknown | Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO NCT04548284 | Sun Yat-sen University | Phase 3 |
| Completed | Effects of Atorvastatin in Graves' Orbitopathy (GO) NCT03110848 | University of Pisa | Phase 2 |
| Unknown | Natural History and Risk Factors of TAO NCT03515863 | Sun Yat-sen University | — |
| Recruiting | Treatment of Graves´ophthalmopathy with Simvastatin (GO-S) NCT03131726 | Lund University | Phase 3 |
| Completed | 99Tc-MDP for Thyroid-Associated Ophthalmopathy NCT03948191 | Dalian University | Phase 4 |
| Completed | Establishment of Multimodal-multiparametric Progressive Prediction Models for Thyroid Associated Ophthalmopath NCT06585592 | Shanghai Changzheng Hospital | — |
| Unknown | Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Supe NCT03107078 | Jie Shen | Phase 4 |
| Completed | New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression NCT02693808 | Haukeland University Hospital | N/A |
| Unknown | Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy NCT02203682 | Sun Yat-sen University | Phase 2 |
| Completed | Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease NCT01868997 | Amgen | Phase 2 |
| Completed | The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy NCT01579539 | Medical University of Vienna | Phase 3 |
| Completed | Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamc NCT01599273 | Yonsei University | Phase 4 |
| Completed | Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmo NCT02766660 | Neon Hospital | N/A |
| Completed | Trial of Rituximab for Graves' Ophthalmopathy NCT00595335 | Rebecca Bahn | Phase 2 / Phase 3 |
| Terminated | Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment NCT00288522 | Ipsen | Phase 2 |
| Completed | Rituximab in the Treatment of Graves' Disease NCT00150111 | Odense University Hospital | Phase 1 / Phase 2 |